Comparison of Neoadjuvant Chemotherapy Plus Interval Debulking Surgery and Primary Debulking Surgery in Patients with Stage III and IV Ovarian Carcinoma: A Multicenter Real Life Experience

被引:0
|
作者
Yilmaz, Mukaddes [1 ]
Basak, Mustafa [2 ]
Ozyukseler, Deniz Tataroglu [3 ]
Yildirim, Mahmut Emre [4 ]
Arik, Zafer [5 ]
Salman, Mehmet Coskun [6 ]
Gultekin, Murat [6 ]
Akgor, Utku [7 ]
Inci, Bediz Kurt [8 ]
Gurler, Fatih [9 ]
Yucel, Kadriye Bir [10 ]
Savas, Gozde [10 ]
Onan, Mehmet Anil
Sunar, Veli [12 ]
Meydanli, Mehmet Mutlu [11 ,13 ]
Yazici, Ozan
Ozet, Ahmet [10 ]
机构
[1] Sivas Cumhuriyet Univ, Dept Med Oncol, Fac Med, Sivas, Turkiye
[2] Gazi Osman Pasa Univ, Dept Med Oncol, Fac Med, Tokat, Turkiye
[3] Fethi Sekin State Hosp, Dept Med Oncol, Elazig, Turkiye
[4] Dr Lutfi Kirdar Kartal Training & Res Hosp, Dept Med Oncol, Istanbul, Turkiye
[5] Hacettepe Univ, Dept Med Oncol, Canc Inst, Ankara, Turkiye
[6] Hacettepe Univ, Dept Gynecol Oncol, Fac Med, Ankara, Turkiye
[7] Ankara Numune Training & Res Hosp, Dept Gynecol Oncol, Ankara, Turkiye
[8] Kirsehir Training & Res Hosp, Dept Med Oncol, Kirsehir, Turkiye
[9] Univ Hlth Sci, Dr Abdurrahman Yurtaslan Oncol Training & Res Hos, Dept Med Oncol, Ankara, Turkiye
[10] Gazi Univ, Dept Med Oncol, Fac Med, Ankara, Turkiye
[11] Gazi Univ, Dept Gynecol Oncol, Fac Med, Ankara, Turkiye
[12] Aydin Ataturk State Hosp, Dept Med Oncol, Aydin, Turkiye
[13] Med Pk Hosp, Dept Gynecol Oncol, Gaziantep, Turkiye
关键词
Interval debulking; neoadjuvant chemotherapy; ovarian carcinoma; primary debulking; CANCER; SURVIVAL; CYTOREDUCTION; OUTCOMES;
D O I
10.5505/tjo.2023.3883
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
OBJECTIVE The aim of the study is to compare treatment outcomes of the patients with federation of gynecology and obstetrics stages III and IV ovarian carcinomas, who underwent interval debulking surgery after neoadjuvant chemotherapy (NACT), and patients who underwent adjuvant chemotherapy after primary debulking surgery (PDS). METHODS Patients from four centers (n=183) were retrospectively evaluated. Of the patients, 91 (50%) were in the PDS group and 92 (50%) in the NACT group. RESULTS In the NACT group patients have advanced age, poor performance status, high levels of CA125, and advanced disease stage compared with the PDS group (p<0.050). Of the patients receiving NACT, 14 (15%) had a complete response, and 68 (74%) had a partial response. The R0 rate was higher in the PDS group (p=0.018). In univariate analysis, poor prognostic factors affecting OS were NACT in the treatment protocol (p<0.001), poor performance status (p<0.001), advanced age (<70 vs. >= 70, p=0.002), advanced clinical stage (p=0.042), and localization of the tumor with the largest diameter outside the omentum and ovary at the time of diagnosis (p=0.029). In the multivariate analysis, the presence of NACT (HR: 2.30, 95% CI: 1.25-4.23, p=0.007) and poor performance (HR: 2.52, 95% CI: 1.18-5.10, p=0.017) were independent poor prognostic factors for OS. CONCLUSION In the study, OS was better in the PDS group than in the NACT group. This result was thought to be associated with the NACT group having more disadvantageous characteristics (advanced age, poor performance, high CA125 level, advanced stage, etc.).
引用
收藏
页码:323 / 332
页数:10
相关论文
共 50 条
  • [31] Rethinking Radical Surgery in Interval Debulking Surgery for Advanced-Stage Ovarian Cancer Patients Undergoing Neoadjuvant Chemotherapy
    Lee, Yong Jae
    Lee, Jung-Yun
    Nam, Eun Ji
    Kim, Sang Wun
    Kim, Sunghoon
    Kim, Young Tae
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (04)
  • [32] Delay in interval debulking surgery after neoadjuvant chemotherapy in ovarian cancer
    Habib, M.
    Khalil, K. Azam
    Saeed, A.
    Usman, M.
    Khattak, S.
    Syed, A. Ali
    BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2024, 131 : 51 - 51
  • [33] Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and peritoneal cancers in phase III randomized trial: JCOG0602.
    Onda, Takashi
    Yoshikawa, Hiroyuki
    Shibata, Taro
    Nakamura, Kenichi
    Satoh, Toyomi
    Saito, Toshiaki
    Kasamatsu, Takahiro
    Nakanishi, Toru
    Nogawa, Takayoshi
    Saitou, Motoaki
    Ushijima, Kimio
    Kobayashi, Hiroaki
    Takano, Tadao
    Kawana, Kei
    Yokota, Harushige
    Takano, Masashi
    Takeshima, Nobuhiro
    Yaegashi, Nobuo
    Konishi, Ikuo A.
    Kamura, Toshiharu
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [34] Advanced endometrial carcinoma: primary debulking surgery or neoadjuvant chemotherapy?
    Guyon, Frederic
    Stoeckle, Eberhard
    Thomas, Laurence
    Petit, Adeline
    Sire, Marie
    Floquet, Anne
    BULLETIN DU CANCER, 2012, 99 (01) : 43 - 49
  • [35] Comparison of diaphragmatic surgery at primary or interval debulking in advanced ovarian carcinoma: An analysis of 163 patients
    Tsolakidis, Dimitris
    Amant, Frederic
    Leunen, Karin
    Cadron, Isabelle
    Neven, Patrick
    Vergote, Ignace
    EUROPEAN JOURNAL OF CANCER, 2011, 47 (02) : 191 - 198
  • [36] Neoadjuvant chemotherapy versus primary debulking surgery in advanced ovarian cancer
    Vergote, IB
    De Wever, I
    Decloedt, J
    Tjalma, W
    Van Gramberen, M
    van Dam, P
    SEMINARS IN ONCOLOGY, 2000, 27 (03) : 31 - 36
  • [37] ROLE OF ROBOTIC SURGERY FOR INTERVAL DEBULKING OF OVARIAN CANCER AFTER NEOADJUVANT CHEMOTHERAPY
    Press, J.
    Bondurant, A.
    Drescher, C.
    Musa, F.
    Shah, C.
    Veljovich, D.
    Kretzer, N.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 : A135 - A135
  • [38] Laparoscopic interval debulking surgery for advanced ovarian cancer after neoadjuvant chemotherapy
    Jorgensen, K.
    Melamed, A.
    Bradford, L.
    Wang, V.
    Chang, H.
    Rauh-Hain, J. A.
    Schorge, J.
    GYNECOLOGIC ONCOLOGY, 2020, 159 : 49 - 50
  • [39] Minimally invasive interval debulking surgery after neoadjuvant chemotherapy for ovarian cancer
    Seagle, B. L. L.
    Yang, J.
    Kocherginsky, M.
    Shahabi, S.
    GYNECOLOGIC ONCOLOGY, 2018, 149 (03) : 629 - 630
  • [40] Microscopic residual carcinoma at interval debulking surgery after neoadjuvant chemotherapy in patients with IIIc/IV Mullerian carcinoma.
    Nishikimi, Kyoko
    Tate, Shinichi
    Kato, Kazuyoshi
    Kiyokawa, Takako
    Shozu, Makio
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)